Segall Bryant & Hamill LLC Buys Shares of 20,802 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Segall Bryant & Hamill LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 20,802 shares of the company’s stock, valued at approximately $8,600,000.

Several other hedge funds have also modified their holdings of the company. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $31,000. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth $38,000. Finally, Crews Bank & Trust purchased a new position in IDEXX Laboratories during the 4th quarter worth $41,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $417.71 on Thursday. The firm’s fifty day moving average is $437.26 and its two-hundred day moving average is $443.87. The firm has a market cap of $33.86 billion, a price-to-earnings ratio of 39.15, a PEG ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88.

Analysts Set New Price Targets

Several equities research analysts have weighed in on IDXX shares. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Bank of America boosted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.